$-0.96 EPS Expected for Revance Therapeutics, Inc. (RVNC); Quest Diagnostics (DGX) SI Decreased By 8.06%

Quest Diagnostics Incorporated (NYSE:DGX) Logo

Quest Diagnostics Incorporated (NYSE:DGX) had a decrease of 8.06% in short interest. DGX’s SI was 2.92 million shares in February as released by FINRA. Its down 8.06% from 3.18M shares previously. With 976,800 avg volume, 3 days are for Quest Diagnostics Incorporated (NYSE:DGX)’s short sellers to cover DGX’s short positions. The SI to Quest Diagnostics Incorporated’s float is 2.26%. The stock decreased 0.59% or $0.52 during the last trading session, reaching $88.57. About 108,151 shares traded. Quest Diagnostics Incorporated (NYSE:DGX) has declined 9.48% since February 11, 2018 and is downtrending. It has underperformed by 9.48% the S&P500. Some Historical DGX News: 09/04/2018 – New Survey: False Beliefs about Sexual Risk, Poor Physician-Patient Communication May Impede STD Screening in Young Women; 14/03/2018 – QUEST DIAGNOSTICS INC DGX.N : MORGAN STANLEY RAISES TO EQUAL-WEIGHT FROM UNDERWEIGHT; 25/05/2018 – Quest Diagnostics Closes Above 50-Day Moving Average; 02/04/2018 – Humana, MultiPlan, Optum, Quest Diagnostics and UnitedHealthcare Launch Blockchain-Driven Effort to Tackle Care Provider Data Issues; 19/04/2018 – QUEST DIAGNOSTICS INC QTRLY ADJUSTED DILUTED EPS EXCLUDING AMORTIZATION OF $1.52; 23/05/2018 – Physicians Lack the Time and Tools to Discover Hidden Risks in Patients with Chronic Conditions, Finds Study from Quest Diagnos; 19/04/2018 – DJ Quest Diagnostics Incorporated, Inst Holders, 1Q 2018 (DGX); 16/03/2018 – Cal EMA Spills: SPILL Report – Quest Diagnostics – 03/16/2018 01:25 PM; 09/04/2018 – New Survey: False Beliefs about Sexual Risk, Poor Physician-Patient Communication May lmpede STD Screening in Young Women; 19/04/2018 – Quest Diagnostics 1Q EPS $1.27

Analysts expect Revance Therapeutics, Inc. (NASDAQ:RVNC) to report $-0.96 EPS on February, 27.They anticipate $0.18 EPS change or 15.79% from last quarter’s $-1.14 EPS. After having $-0.91 EPS previously, Revance Therapeutics, Inc.’s analysts see 5.49% EPS growth. The stock decreased 1.17% or $0.2 during the last trading session, reaching $16.91. About 34,918 shares traded. Revance Therapeutics, Inc. (NASDAQ:RVNC) has declined 29.56% since February 11, 2018 and is downtrending. It has underperformed by 29.56% the S&P500. Some Historical RVNC News: 02/04/2018 – Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 lnjectable; 24/05/2018 – Revance Announces Publication of Positive 24-Week Duration of Effect Results from Cervical Dystonia Phase 2 Trial in Movement; 08/05/2018 – Revance Therapeutics 1Q Loss/Shr 97c; 18/04/2018 – Retrotope Announces Peer-Reviewed Publication of Positive Phase 1b/2a Findings for RT001 in Friedreich’s Ataxia; 26/03/2018 – Revance to Host Investor Day on April 19, 2018; 13/03/2018 – REVANCE IN CONTROLLED EQUITY OFFERING SALES PACT UP TO $125M; 15/05/2018 – Revance to Participate in the UBS Global Healthcare Conference; 18/04/2018 – Retrotope Announces Peer-Reviewed Publication of Positive Phase 1b/2a Findings for RT001 in Friedreich’s Ataxia; 24/05/2018 – REVANCE REPORTS PUBLICATION FROM CERVICAL DYSTONIA PHASE 2; 02/04/2018 – Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable

More notable recent Revance Therapeutics, Inc. (NASDAQ:RVNC) news were published by: Globenewswire.com which released: “CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors – GlobeNewswire” on February 11, 2019, also Streetinsider.com with their article: “Revance Therapeutics (RVNC) Announces Proposed Approx. $100M Common Share Offering – StreetInsider.com” published on January 15, 2019, Streetinsider.com published: “After-Hours Movers 01/15: (UAL) (AAL) (LUV) Higher; (EFII) (RVNC) (PCG) (more…) – StreetInsider.com” on January 15, 2019. More interesting news about Revance Therapeutics, Inc. (NASDAQ:RVNC) were released by: Investorplace.com and their article: “10 Monster Growth Stocks to Buy for 2019 and Beyond – Investorplace.com” published on February 08, 2019 as well as 247Wallst.com‘s news article titled: “Signet Jewelers, Revance Therapeutics Tumble Into Thursday’s 52-Week Low Club – 24/7 Wall St.” with publication date: January 17, 2019.

Investors sentiment increased to 1.47 in 2018 Q3. Its up 0.16, from 1.31 in 2018Q2. It is positive, as 10 investors sold Revance Therapeutics, Inc. shares while 22 reduced holdings. 16 funds opened positions while 31 raised stakes. 32.53 million shares or 1.08% less from 32.89 million shares in 2018Q2 were reported. 438,869 are owned by Northern. Federated Inc Pa stated it has 0% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC). 11,312 were reported by Nottingham Advsr. Us Fincl Bank De reported 760 shares. Citigroup Incorporated accumulated 8,576 shares. Moreover, Bank & Trust Of America Corporation De has 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 82,600 shares. Alps Advisors invested 0.01% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC). Tekla Cap Management Ltd stated it has 77,919 shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 1,193 shares or 0% of the stock. California State Teachers Retirement Systems holds 0% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 50,206 shares. Arrowmark Colorado invested 0.47% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC). Renaissance Techs reported 176,454 shares. Essex Invest Management Company Limited Liability Corporation has invested 0.26% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Parametric Port Assocs Limited Co, a Washington-based fund reported 46,834 shares. Teachers Retirement Systems Of The State Of Kentucky reported 16,423 shares stake.

Since November 9, 2018, it had 0 insider purchases, and 4 selling transactions for $80,454 activity. On Friday, November 9 Allouche Cyril sold $51,899 worth of Revance Therapeutics, Inc. (NASDAQ:RVNC) or 2,188 shares.

Among 3 analysts covering Revance Therapeutics (NASDAQ:RVNC), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Revance Therapeutics had 3 analyst reports since September 17, 2018 according to SRatingsIntel. The stock has “Buy” rating by Guggenheim on Friday, November 16. The stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) has “Market Perform” rating given on Monday, September 17 by JMP Securities.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company has market cap of $739.93 million. The company's lead drug candidate is DaxibotulinumtoxinA for injection , which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It currently has negative earnings. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $12.05 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 14.3 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

Investors sentiment increased to 1.06 in 2018 Q3. Its up 0.13, from 0.93 in 2018Q2. It increased, as 33 investors sold Quest Diagnostics Incorporated shares while 189 reduced holdings. 77 funds opened positions while 159 raised stakes. 109.58 million shares or 1.19% less from 110.90 million shares in 2018Q2 were reported. Amica Retiree Medical accumulated 0.09% or 1,058 shares. Centurylink Inv Mngmt reported 0.45% in Quest Diagnostics Incorporated (NYSE:DGX). Legacy Ptnrs Incorporated holds 0.11% or 2,259 shares. Moreover, Bank & Trust Of Nova Scotia has 0.04% invested in Quest Diagnostics Incorporated (NYSE:DGX). Da Davidson & Co invested in 0.01% or 6,715 shares. United Kingdom-based Polar Capital Llp has invested 0.14% in Quest Diagnostics Incorporated (NYSE:DGX). New York-based Mackay Shields Lc has invested 0.02% in Quest Diagnostics Incorporated (NYSE:DGX). Blair William And Company Il reported 0% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Delta Asset Limited Company Tn reported 43 shares. 65,242 are owned by Pnc Service Gru. 569,377 are owned by Ubs Asset Management Americas. Hartford Finance Management Inc has 0% invested in Quest Diagnostics Incorporated (NYSE:DGX) for 10 shares. Camelot Portfolios Ltd Company holds 0.14% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX) for 2,925 shares. Jefferies Group Incorporated Limited Co holds 0.09% or 130,478 shares in its portfolio. Brown Advisory stated it has 0% in Quest Diagnostics Incorporated (NYSE:DGX).

Among 10 analysts covering Quest Diagnostics (NYSE:DGX), 4 have Buy rating, 1 Sell and 5 Hold. Therefore 40% are positive. Quest Diagnostics had 13 analyst reports since September 14, 2018 according to SRatingsIntel. The firm has “Overweight” rating by Barclays Capital given on Friday, November 30. The stock of Quest Diagnostics Incorporated (NYSE:DGX) earned “Neutral” rating by Citigroup on Wednesday, October 24. The firm earned “Outperform” rating on Wednesday, October 24 by Credit Suisse. Goldman Sachs downgraded Quest Diagnostics Incorporated (NYSE:DGX) on Friday, November 30 to “Neutral” rating. As per Wednesday, October 24, the company rating was maintained by Barclays Capital. The firm earned “Underperform” rating on Thursday, January 3 by Bank of America. The stock of Quest Diagnostics Incorporated (NYSE:DGX) earned “Overweight” rating by Morgan Stanley on Friday, November 30. The rating was maintained by Argus Research with “Buy” on Friday, September 14. The stock has “Buy” rating by Canaccord Genuity on Wednesday, October 24. Credit Suisse maintained it with “Outperform” rating and $103 target in Friday, November 30 report.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Positions Chart

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.